Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Accumulated Expenses (2023 - 2025)

Bioregenx's Accumulated Expenses history spans 3 years, with the latest figure at $434370.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $434370.0 for Q4 2025, up 2.38% from a year ago — trailing twelve months through Dec 2025 was $434370.0 (up 2.38% YoY), and the annual figure for FY2025 was $434370.0, up 2.38%.
  • Accumulated Expenses for Q4 2025 was $434370.0 at Bioregenx, up from $380599.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $459732.0 in Q1 2025 to a low of $321897.0 in Q1 2024.
  • The 3-year median for Accumulated Expenses is $398058.0 (2024), against an average of $395001.2.
  • Peak annual rise in Accumulated Expenses hit 42.82% in 2025, while the deepest fall reached 0.86% in 2025.
  • Year by year, Accumulated Expenses stood at $346677.0 in 2023, then increased by 22.38% to $424277.0 in 2024, then grew by 2.38% to $434370.0 in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $434370.0, $380599.0, and $405495.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.